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Background: The association of severe strongyloides with HTLV-I is well known; however, the seroprevalence of 
HTLV-I in other groups with strongyloidiasis is still unknown. We conducted a prospective study in patients with 
intestinal strongyloidiasis without known immunodepression who failed to respond to standard therapy with 
ivermectin or thiabendazole (failure was defined as one positive stool examination at the post-therapy follow up). 
All these patients were tested for HTLV-I by ELISA and Western Blot. 
Results: Forty seven patients were evaluated: 74.5% (35 out of 47) were HTLV-I positive, without significant 
difference between males (76%) and females (72.7%). 
Conclusions: We recommend that all patients with uncomplicated intestinal strongyloidiasis, who fail standard 
therapy, be studied for HTLV-I infection. 
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Strongyloides stercoralis (S. stercoralis) is a soil- 
transmitted intestinal nematode with a worldwide 
distribution but with a higher prevalence in tropical 
regions. Global prevalence is estimated at 60 million 
people and infection is usually acquired by penetration 
of the skin by filariform 1arvae.l 
Low-grade, most often clinically asymptomatic, 
internal autoinfective cycles may develop in a propor- 
tion of untreated immunocompetent individuals; an 
intact immune system apparently is able to prevent 
widespread dissemination. Occasionally, more severe 
cases of strongyloides autoinfection are detected, with 
pulmonary involvement and strongyloides larvae in 
sputum. In those that are severely immunosuppressed, 
massive dissemination of invasive filariform larvae from 
the intestine to the lung, liver, central nervous system, or 
kidney, frequently results in a fatal outcome.2 The results 
of several studies have documented an association 
between strongyloides infection and malignancy, severe 
malnutrition, corticosteroid therapy and renal trans- 
plantion. We and others have recently described the 
strong association between disseminated strongyloidiasis 
and HTLV-I infection in otherwise healthy patients.&‘j 
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A three-day course of thiabendazole has been 
shown to have an efficacy of 88% or greater in uncom- 
plicated intestinal infection. However, the high incidence 
of severe nausea and dizziness often limit the ability 
of patients to complete the full-course.7 Recently, 
ivermectin in one or two consecutive single daily doses 
has given a cure rate of 88% with few side effects and 
excellent tolerance.8 The experience at our institution 
with uncomplicated infection has been similar. The 
objective of the present study was to evaluate for con- 
comitant HTLV-I infection this group of patients who 
fail to respond to standard therapy. 
MATERIAL AND METHODS 
Patients who met the following criteria were included: 
(a) 
(b) 
cc> 
Patients with gastrointestinal discomfort such as 
abdominal pain, diarrhea, and weight loss without 
other systemic or pulmonary signs, and in whom 
S. stercoralis is detected in stools but not in sputum 
(with l-2 negative tests); Patients with two or more 
organs involved with S. stercoralis, and who in 
addition had positive sputum test for S. stercoralis 
defined in our institution as having hyperinfestation; 
Patients who received standard treatment against 
intestinal strongyloidiasis: thiabendazole 25 mg/kg/ 
day for three days (maximum dose 2 gm) (Merck 
Sharp & Dohme) or ivermectin (Merck Sharp & 
Dohme, France) 200 mcglkglday as a single dose, 
which was provided free of charge to the patients. 
Patients who underwent post-treatment stool 
examinations at 1 week, 1 month, or at least three 
times within 6 months after treatment (minimum 
three post-treatment examinations), with the use of 
the Baermann method modified by Lumbreras.9 
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(d) Patient who had not returned to an endemic area 
within 6 months following treatment. (Lima was 
defined as a non-endemic area.) 
Therapeutic failure was defined by the detection of S. 
stercoralis larvae in stools at any one of the follow-up 
tests. Patients with AIDS/HIV on chemotherapy for 
cancer, or on systemic corticosteroids, were excluded. 
HTLV-I ELISA (Genetic Systems, Seattle, WA) was 
performed on serum as described. Definition of HTLV- 
I positivity required a positive confirmatory Western 
blot test.lO Participation in the study was voluntary and 
all patients signed an informed consent. 
RESULTS 
Between 1990 and 1998, 47 patients (25 males:22 
females) were enrolled who met the inclusion criteria 
for strongyloides treatment failure; 41/47 had some 
positive stools cultures during the first month, 6/47 over 
one to six months. The majority of cases had two to three 
positive stools cultures and needed a second cycle of our 
standard therapy. As shown in Table I, overall HTLV-I 
seropositivity was high at 74.5% (35/47). HTLV-I 
seropositivity did not differ by gender. Children under 
10 years of age were uniformly suffering from clinical 
malnutrition and only 2/6 (33 %) were HTLV-I positive. 
In the authors’ institution, 50-60 patients a year 
with S. stercoralis are seen; only those patients were 
entered who could be appropriately followed. No bias 
was found in patient selection. 
DISCUSSION 
The association between HTLV-I and strongyloides was 
initially recognized in Kagoshima,4 an HTLV-I endemic 
tropical region in Japan. In Jamaica, 58% of the patients 
with strongyloides in stools were also HTLV-I sero- 
positive compared with a seropositivity of 15% in those 
with negative stools. However, neither of the above 
studies provided any data on the clinical manifestations 
of the strongyloides infection in their patients.5 
In the authors’ recently published study, we 
described patients in Peru with clinical manifestations of 
disseminated hyperinfection with S. stercoralis. Using 
the parasitologic criteria of a positive sputum examin- 
ation for S. stercoralis larvae, the authors found that 86% 
of these individuals were HTLV-I positive.6 Such patients 
with clearly disseminated hyperinfection require 
prolonged or repeated treatment. This is because only 
adult worms, and not immature migrating larvae in the 
lung and other organs are killed by thiabendazole or 
ivermectin. In the authors’ institution, since 1970, for 
patients with sputum positive and hyperinfection a 
standard regimen was used of thiabendazole 25 mg/kg/ 
day for 3 days and then lg daily for 15-30 days with 
excellent results.li Recently, with ivermectin the 2-day 
cycle was repeated two or three times at 15-30 days 
intervals and there is a cure rate of >90% in these 
severe chronic cases with positive sputum examination 
(Terashima A. Unpublished data.) 
In the present study, the authors did not examine 
HTLV-I seroprevalence rates in a matched control 
group with uncomplicated intestinal strongyloidiasis 
that was completely responsive to therapy; such patients 
respond to three days of thiabendazole or a single dose 
of ivermectin with a cure rate of >90%. The rate of 
HTLV-I in such uncomplicated patients in a previously 
published study from the same patient population was 
10% and for the healthy control group 3.9%.11 Patients 
non-responsive to the therapy have a 74.5% rate of 
HTLV-I seropositivity (if the children are excluded, the 
rate of HTLV-I infection is 80%). One Japanese study 
has recognized a low therapeutic efficacy of standard 
treatment against strongyloides in patients with HTLV- 
I;12 however, no details of the clinical manifestations of 
infection was provided for those patients. 
Because of the lack of larvae in the sputum, the 47 
patients described here are not recognized as severe 
strongyloidiasis but would be classified as uncompli- 
cated intestinal strongyloidiasis. Some more advanced 
degree of autoinfection or dissemination has likely 
occurred, but without detectable larvae in the sputum. 
Most authorities, using current paradigms, would not 
allow these individuals to be considered as disseminated 
hyperinfection. 2,4 This type of patient has been seen as 
early as 1973 and they have been described by Alvarez.r” 
At that time, however, HTLV-I was not yet described; 
these patients are ‘intermediate’ between uncompli- 
cated intestinal strongyloidiasis and disseminated hyper- 
infection. This ‘intermediate’ clinical group described as 
failure to respond to standard treatment, here likely 
represents an earlier phase in the progression of the 
immunosuppression against strongyloidiasis due to 
HTLV-I. None of the patients in this study had HAM/ 
TSP or lymphoma/leukemia (ATLL). 
HTLV-I does not seem to predispose to the S. 
stercoralis infection, but appears to alter the clinical 
patterns.6 Recently, Neva et a1.i3 published that the 
PBMC in HTLV-I-infected individuals spontaneously 
produce a high level of interferon IFN-)I and produce 
little IL-4 in response to mitogenic stimulation. This 
would relate to a poor ability to make IgE immuno- 
globulin isotype, thought to play the major role in host 
defense against strongyloides. 
Table 1. HTLV-I seropositivity in patients with intestinal 
strongyloidiasis and parasitologic failure to standard therapy 
-c 10 years 
1 O-29 years 
30-49 years 
> 50 years 
Male Female 
N=25 N=22 Total 
2/S O/l 216 
6l7 316 9/I 3 
818 517 13115 
3/s at8 1 l/13 
19125 (76%) 16/22 (72.7%) 35/47 (74.5%) 
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In the Amazon Region of Peru, the prevalence of 
strongyloides infection is estimated to be 30-70%.14 
Severe clinical manifestations are mostly observed in 
malnourished children but not in adults, since HTLV-I is 
not endemic in the jungle. The Andean Valleys are 
endemic for HTLV-I but not for strongyloides. Fifty to 
sixty percent of patients were born in the Andean region 
but they had in common a history of temporary residence 
in the Amazon Region to find temporary work; they 
then acquired strongyloidiasis and, because of their 
HTLV-I status, developed the more severe clinical 
manifestations of infection. This internal migration of 
the Andean population to the Amazon region has 
permitted the association of these two infections and 
created a new health problem in Peru. In the cases of 
HAM/TSP (HTLV-I myelopathy or tropical spastic 
paraparesis), 50% were born in the Andean cities.15 
In conclusion, all patients with uncomplicated 
intestinal strongyloidiasis, who fail standard therapy and 
who do not have any other obvious immunosuppression, 
should be studied for HTLV-I infection. 
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